DataMEDS AI (MEDS)
Market Price (9/21/2026): $4.0 | Market Cap: $10.3 MilSector: Health Care | Industry: Health Care Distributors
DataMEDS AI (MEDS)
Market Price (9/21/2026): $4.0Market Cap: $10.3 MilSector: Health CareIndustry: Health Care Distributors
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Artificial Intelligence, and Digital Health & Telemedicine. Themes include AI Software Platforms, AI in Healthcare Management, Show more. | Weak multi-year price returns2Y Excs Rtn is -31%, 3Y Excs Rtn is -66% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -58 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -719% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -78%, Rev Chg QQuarterly Revenue Change % is -77% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 357% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -171%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -183% High stock price volatilityVol 12M is 736% Key risksMEDS key risks include [1] failure to achieve widespread adoption for its marketplace platforms against intense competition and [2] cybersecurity breaches of sensitive patient and pharmaceutical data held on its MedCheks and Bonum Health Hub platforms. |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, and Digital Health & Telemedicine. Themes include AI Software Platforms, AI in Healthcare Management, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -31%, 3Y Excs Rtn is -66% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -58 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -719% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -78%, Rev Chg QQuarterly Revenue Change % is -77% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 357% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -171%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -183% |
| High stock price volatilityVol 12M is 736% |
| Key risksMEDS key risks include [1] failure to achieve widespread adoption for its marketplace platforms against intense competition and [2] cybersecurity breaches of sensitive patient and pharmaceutical data held on its MedCheks and Bonum Health Hub platforms. |
Qualitative Assessment
AI Analysis | Feedback
DataMEDS AI (MEDS) stock has gained about 5% since it went public on 7/22/2026 because of the following key factors:
1. Strategic Expansion into Oncology with Helomics Acquisition.
DataMEDS AI acquired Helomics and a lab services business on September 15, 2026, for a total purchase value of $1.5 million, structured through common shares and a convertible note. This acquisition thrusts DataMEDS into the oncology field, an area identified with significant need to improve patient outcomes, and includes an AI-driven cancer diagnostics laboratory. The news sparked a substantial rally in MEDS stock, with shares gaining 87% on September 15 and an additional 275% in the subsequent trading session (September 16, 2026).
2. Resolution of Significant Litigation and Liability Reduction.
In fiscal Q3 2026, DataMEDS AI settled a long-standing litigation, extinguishing approximately $19 million in liabilities from its consolidated balance sheet for a cash payment of $450,000. Additionally, the settlement resulted in the retirement of approximately 364,099 common shares. This resolution, announced on September 17-18, 2026, significantly improved the company's financial outlook by removing a substantial debt burden.
Show more
DataMEDS AI (MEDS) stock has gained about 5% since it went public on 7/22/2026 because of the following key factors:
1. Strategic Expansion into Oncology with Helomics Acquisition.
DataMEDS AI acquired Helomics and a lab services business on September 15, 2026, for a total purchase value of $1.5 million, structured through common shares and a convertible note. This acquisition thrusts DataMEDS into the oncology field, an area identified with significant need to improve patient outcomes, and includes an AI-driven cancer diagnostics laboratory. The news sparked a substantial rally in MEDS stock, with shares gaining 87% on September 15 and an additional 275% in the subsequent trading session (September 16, 2026).
2. Resolution of Significant Litigation and Liability Reduction.
In fiscal Q3 2026, DataMEDS AI settled a long-standing litigation, extinguishing approximately $19 million in liabilities from its consolidated balance sheet for a cash payment of $450,000. Additionally, the settlement resulted in the retirement of approximately 364,099 common shares. This resolution, announced on September 17-18, 2026, significantly improved the company's financial outlook by removing a substantial debt burden.
3. Favorable Macroeconomic Trends in the AI in Healthcare Market.
The broader artificial intelligence in healthcare market is experiencing robust growth, providing a positive backdrop for DataMEDS AI. The global AI in healthcare market size is projected to grow from an estimated USD 50.7 billion in 2026 to USD 505.6 billion by 2033, demonstrating a compound annual growth rate (CAGR) of 38.9%. AI adoption is rapidly increasing among both clinicians and patients, indicating a growing demand for the health IT solutions that DataMEDS AI offers through its EinsteinRx™ AI platform and PharmacyChain™ smart contracts technology.
4. Strategic Focus on High-Growth Therapeutic Areas.
Beyond oncology, DataMEDS AI is strategically expanding its services to target critical health issues such as GLP-1 agonist side effects and Long COVID. The company intends to leverage its Health Lives Here app and proprietary blockchain to consolidate electronic health data, aiming to empower patients and reduce data friction for providers. This strategic alignment with high-need and growing therapeutic areas contributes to investor confidence in the company's future revenue streams.
Show less
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
5/31/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| MEDS | ||
| Market (SPY) | 0.9% | -10.8% |
| Sector (XLV) | 12.7% | -2.0% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| MEDS | ||
| Market (SPY) | 11.6% | -10.8% |
| Sector (XLV) | 5.5% | -2.0% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2025 to 9/20/2026| Return | Correlation | |
|---|---|---|
| MEDS | ||
| Market (SPY) | 19.4% | -10.8% |
| Sector (XLV) | 24.1% | -2.0% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2023 to 9/20/2026| Return | Correlation | |
|---|---|---|
| MEDS | ||
| Market (SPY) | 75.6% | -10.8% |
| Sector (XLV) | 32.3% | -2.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MEDS Return | - | - | - | - | - | 30% | 30% |
| Peers Return | -33% | -65% | -1% | -36% | -31% | 37% | -86% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| MEDS Win Rate | - | - | - | - | - | 33% | |
| Peers Win Rate | 37% | 30% | 50% | 38% | 30% | 51% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| MEDS Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -54% | -69% | -53% | -57% | -55% | -40% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, GDRX, AMWL, VEEV, HCAT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)
How Low Can It Go
MEDS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
MEDS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About DataMEDS AI (MEDS)
DataMEDS AI, operating under the symbol MEDS, functions as a technology company primarily focused on the pharmaceutical industry within the United States. At its core, the company operates a robust business-to-business (B2B) web-based marketplace that streamlines commerce between healthcare buyers and sellers of pharmaceuticals, related accessories, and services. Its main objective is to enhance efficiency and connectivity within the drug supply chain.
The company's key offerings include Trxade.com and InventoryRx.com, which are central web-based platforms for pharmaceutical transactions and exchanges. DataMEDS AI further supports independent pharmacies with services like Pharmabayonline, providing crucial data analytics and governmental reimbursement benchmarks, and Trxademso.com, assisting with pricing, distribution, and logistics. Additionally, Trxade Prime consolidates and ships purchase orders from suppliers, directly benefiting pharmacy members on its platform. These services primarily target independent pharmacies and pharmaceutical suppliers and buyers within the healthcare sector.
Beyond its core B2B marketplace, DataMEDS AI has diversified its portfolio to include a retail specialty pharmacy through Community Specialty Pharmacy, LLC. It also ventures into consumer-facing solutions with Delivmeds.com, an app for pharmaceutical product delivery, and MedCheks, a digital health platform empowering patients to manage their health data. Furthermore, Bonum Health Hub offers virtual examination rooms, and Bonum+ provides B2B tools for COVID-19 risk assessment and personal protective equipment. This expansion caters to a broader audience, including individual consumers and healthcare providers seeking telehealth and patient data management solutions.
AI Analysis | Feedback
An Amazon-like marketplace, but specifically for the business-to-business buying and selling of pharmaceuticals.
A Costco or Sam's Club for independent pharmacies, offering a marketplace and tools to optimize their purchasing and operations.
AI Analysis | Feedback
- Trxade.com: A web-based marketplace connecting healthcare buyers and sellers of pharmaceuticals.
- InventoryRx.com: A web-based platform facilitating the exchange of pharmaceutical inventory among healthcare entities.
- Pharmabayonline: Provides proprietary pharmaceutical data analytics and governmental reimbursement benchmark analysis for independent pharmacies.
- RxGuru: An application offering comprehensive pharmaceutical product information.
- Retail Specialty Pharmacy: Operates a physical retail specialty pharmacy for direct pharmaceutical sales.
- Delivmeds.com: A consumer-based app designed for the delivery of pharmaceutical products.
- Trxademso.com: Assists independent retail pharmacies with pricing, distribution, and logistics management.
- Trxade Prime: A service allowing pharmacy members to process, consolidate, and ship purchase orders directly from Trxade suppliers.
- Bonum Health Hub: A virtual examination room service facilitating telehealth consultations.
- Bonum+: A B2B platform for purchasing COVID-19 risk assessment and personal protective equipment tools.
- MedCheks: A healthcare platform enabling patients to consolidate, control, and share their health data via a digital Health Passport.
AI Analysis | Feedback
Major Customers of DataMEDS AI (MEDS)
DataMEDS AI (symbol: MEDS) primarily sells its products and services to other companies, operating as a business-to-business (B2B) marketplace and service provider within the pharmaceutical industry. The provided background information does not list specific named customer companies that are public or private.
Based on the company's description, its major customers are businesses that fall into the following categories:
- Independent Retail Pharmacies: These pharmacies are direct users of DataMEDS AI's platforms and services, including Trxade.com (web-based pharmaceutical marketplace), Pharmabayonline (pharmaceutical data analytics), Trxademso.com (pricing, distribution, and logistics assistance), and Trxade Prime (purchase order processing and consolidation).
- Healthcare Buyers and Sellers of Pharmaceuticals: This category encompasses various entities within the healthcare sector that utilize DataMEDS AI's web-based market platform to enable commerce for pharmaceuticals, accessories, and services.
AI Analysis | Feedback
AI Analysis | Feedback
Suren Ajjarapu – Chairman & Chief Executive Officer
Suren Ajjarapu is the Founder, Chairman, and CEO of TRxADE HEALTH, Inc. (formerly Trxade Group, Inc.). He co-founded the company with Prashant Patel, drawing on their experience as independent pharmacy owners in the Tampa Bay area to address industry challenges. Ajjarapu is an experienced entrepreneur who has founded and led multiple public companies, including Aemetis, Inc. and Sansur Renewable Energy, Inc.. He also co-founded Global Information Technology, Inc., where he served as COO and Director. Known as a skilled executive manager, corporate strategist, fundraiser, and marketer, he has taken approximately six companies public, including three Special Purpose Acquisition Companies (SPACs). He holds an MBA in International Finance from the University of South Florida and completed the Private Equity and Venture Capital Programme at Harvard Business School Executive Education. Ajjarapu was instrumental in getting Trxade Group, Inc. listed on NASDAQ in 2020.
Prashant Patel R.Ph. – Interim CFO, President, COO & Director
Prashant Patel serves as the Interim CFO, President, COO, and Director of Wellgistics Health Inc. (TRxADE HEALTH, Inc.). He also holds the titles of President, COO, and Director for TRxADE HEALTH, Inc.. Patel co-founded Trxade Group (now TRxADE HEALTH) with Suren Ajjarapu. Their background as owners of multiple pharmacies in the Tampa Bay area provided them with direct insight into the pain points and challenges faced by independent pharmacies, which became the foundation for the company's mission.
Jariel Morales – EVP, Trxade, Inc.
Jariel Morales is the Executive Vice President (EVP) of Trxade, Inc., a subsidiary of TRxADE HEALTH, Inc..
AI Analysis | Feedback
Key Risks to DataMEDS AI (Symbol: MEDS)
- Intense Competition and Market Adoption: DataMEDS AI operates various web-based platforms and marketplaces within the pharmaceutical industry. Its success hinges on attracting and retaining a critical mass of healthcare buyers and sellers. The company faces significant competition from established pharmaceutical distributors with entrenched relationships, other technology-driven platforms entering the space, and potentially large pharmacy chains that may develop or expand their own internal systems. Failure to achieve widespread adoption for its platforms or to effectively differentiate its services in a competitive market could severely limit its growth, market share, and profitability.
- Regulatory and Compliance Risks in the Pharmaceutical and Healthcare Industry: Operating in the highly regulated pharmaceutical and healthcare sectors, DataMEDS AI is exposed to substantial regulatory risks. Changes in drug pricing policies, pharmaceutical supply chain regulations, data privacy laws (such as HIPAA), governmental reimbursement benchmarks, or other healthcare regulations could directly impact its business model, increase operational and compliance costs, or restrict the scope and viability of its services and products, including its marketplace, data analytics, and patient health platforms.
- Cybersecurity and Data Security Risks: DataMEDS AI handles a significant amount of sensitive information, including proprietary pharmaceutical data, governmental reimbursement benchmarks, and patient health data via platforms like MedCheks (a digital Health Passport) and Bonum Health Hub. The risk of cyberattacks, data breaches, or other security incidents is substantial. Such events could lead to significant financial losses, damage to its reputation, severe regulatory penalties (e.g., under HIPAA), and a loss of trust from its customers and users, thereby disrupting operations and impacting its business relationships.
AI Analysis | Feedback
The emerging threat to DataMEDS AI stems from the potential expansion of large, well-capitalized technology companies, particularly those already demonstrating a strong interest in the healthcare and pharmaceutical sectors, into the business-to-business (B2B) pharmaceutical marketplace. Companies like Amazon, with its existing logistics infrastructure, B2B marketplace platform (Amazon Business), and recent direct-to-consumer pharmacy initiatives (Amazon Pharmacy), could leverage their scale, technological prowess, and financial resources to enter and rapidly dominate the B2B pharmaceutical distribution and marketplace space. This would directly challenge DataMEDS AI's core offerings such as Trxade.com (web-based pharmaceutical marketplace), InventoryRx.com (pharmaceutical exchange), Trxademso.com (logistics and distribution assistance), and Trxade Prime (order consolidation and shipping), by offering a potentially more efficient, cost-effective, and technologically advanced platform, akin to how digital disruptors have challenged traditional industries.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Peer Outperformance in Health Care Distributors
null| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors ← | 6 | 16.2% | 43.2% | 90.1% | CAH 392% · MCK 346% · COR 168% |
| Managed Health Care | 8 | 40.4% | -5.3% | 2.3% | OSCR 84% · HQY 56% · ELV 17% |
| Health Care Services | 20 | 21.1% | 37.6% | -0.3% | HIMS 239% · RDNT 173% · DGX 76% |
| Health Care Facilities | 24 | 6.0% | 6.5% | -4.5% | NHC 271% · THC 261% · ENSG 129% |
| Health Care Equipment | 50 | -2.7% | -0.2% | -21.1% | POCI 11050% · UFPT 341% · GKOS 222% |
| Pharmaceuticals | 62 | -10.5% | 14.8% | -38.6% | LQDA 2472% · INDV 1099% · ETON 1051% |
| Health Care Supplies | 12 | 14.1% | -8.9% | -39.7% | LNTH 287% · HAE 54% · MMSI 20% |
| Life Sciences Tools & Services | 109 | 4.3% | -11.3% | -68.4% | SNWV 1757% · MEDP 231% · NTRA 199% |
| Health Care Technology | 21 | -25.8% | -52.6% | -79.2% | SPOK 68% · HSTM 3% · VEEV -13% |
| Biotechnology | 364 | 0.6% | -21.7% | -79.4% | CELZ 1280% · DNTH 1221% · ELVN 1069% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 5.03 |
| Mkt Cap | 1.1 |
| Rev LTM | 539 |
| Op Inc LTM | -44 |
| FCF LTM | 62 |
| FCF 3Y Avg | 49 |
| CFO LTM | 115 |
| CFO 3Y Avg | 90 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -4.8% |
| Rev Chg 3Y Avg | 1.1% |
| Rev Chg Q | -8.3% |
| QoQ Delta Rev Chg LTM | -2.2% |
| Op Inc Chg LTM | 25.0% |
| Op Inc Chg 3Y Avg | 33.0% |
| Op Mgn LTM | -8.2% |
| Op Mgn 3Y Avg | -7.1% |
| QoQ Delta Op Mgn LTM | 0.0% |
| CFO/Rev LTM | 10.1% |
| CFO/Rev 3Y Avg | 11.7% |
| FCF/Rev LTM | 3.5% |
| FCF/Rev 3Y Avg | 6.1% |
Price Behavior
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.47 | 0.28 | 1.51 | 0.16 | -2.13 | 1.70 |
| Up Beta | 1.92 | 8.89 | 1.01 | -6.02 | 2.33 | 1.71 |
| Down Beta | -16.78 | -0.71 | 1.31 | -1.87 | 4.65 | -5.32 |
| Up Capture | -384% | -136% | -79% | -30% | -14% | -1% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 7 | 9 | 9 | 9 | 9 | 9 |
| Down Capture | 1568% | 702% | 373% | 217% | 136% | 76% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 14 | 19 | 19 | 19 | 19 | 19 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MEDS | |
|---|---|---|---|---|
| MEDS | 5.0% | 735.9% | 1.61 | - |
| Sector ETF (XLV) | 24.4% | 16.1% | 1.16 | -2.0% |
| Equity (SPY) | 16.9% | 12.9% | 0.94 | -10.8% |
| Gold (GLD) | 19.1% | 29.3% | 0.60 | -9.9% |
| Commodities (DBC) | 46.3% | 20.6% | 1.73 | -19.0% |
| Real Estate (VNQ) | 4.9% | 13.6% | 0.10 | -7.0% |
| Bitcoin (BTCUSD) | -30.6% | 44.3% | -0.70 | -5.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MEDS | |
|---|---|---|---|---|
| MEDS | 1.0% | 735.9% | 1.61 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.24 | -2.0% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | -10.8% |
| Gold (GLD) | 19.1% | 18.8% | 0.83 | -9.9% |
| Commodities (DBC) | 11.2% | 19.5% | 0.45 | -19.0% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | -7.0% |
| Bitcoin (BTCUSD) | 12.5% | 52.5% | 0.42 | -5.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MEDS | |
|---|---|---|---|---|
| MEDS | 0.5% | 735.9% | 1.61 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | -2.0% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | -10.8% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | -9.9% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | -19.0% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.18 | -7.0% |
| Bitcoin (BTCUSD) | 62.6% | 66.2% | 1.02 | -5.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 9/21/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/18/2026 | -7.4% | -12.8% | 307.4% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 1 |
| # Negative | 1 | 1 | 0 |
| Median Positive | 307.4% | ||
| Median Negative | -7.4% | -12.8% | |
| Max Positive | 307.4% | ||
| Max Negative | -7.4% | -12.8% | |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/18/2026 | -7.4% | -12.8% | 307.4% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 1 |
| # Negative | 1 | 1 | 0 |
| Median Positive | 307.4% | ||
| Median Negative | -7.4% | -12.8% | |
| Max Positive | 307.4% | ||
| Max Negative | -7.4% | -12.8% | |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.